GRPR and neoplasm: Liu et al. pioneered the use of 64Cu-labeled RGD-BBN heterodimers for dual-receptor targeting of integrin αvβ3 and GRPR, demonstrating improved tumor uptake over single-receptor monomers or their mixtures [173].